Study of Pridopidine for the Treatment of Participants With Huntington's Disease
- Study Title
- A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease
- Teva Identifier
- ACR16 C009
- ClinicalTrials.gov Identifier
- NCT00724048
- Study Status
- Completed
- Trial Condition(s)
- Huntington Disease
- Interventions
- Drug: ACR16 10 mg | Drug: ACR16 22.5 mg | Drug: ACR16 45 mg | Other: Placebo
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 30 Years and older
- Trial Duration
- 10/01/2008 - 06/01/2011
- Phase
- Phase 2/3
